RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BARD1 Life Sciences Stock

BARD1 Life Sciences Stocks 2024

BARD1 Life Sciences Stocks

77.27 M

Ticker

BD1.AX

ISIN

AU000000BD12

WKN

A2AL50

In 2024, BARD1 Life Sciences had 77.27 M outstanding stocks, a 70.01% change from the 45.45 M stocks in the previous year.

The BARD1 Life Sciences Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
202177.27
202045.45
201941.77
201823.9
201718.97
2016248.47
2015113.01
2014113.01
2013113.01
2012113.01
2011100.53
201083.24
200967.56
200841.62
200740.81
200634.45
200523.33
200415.63
200312.81
20029.57

BARD1 Life Sciences shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue BARD1 Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates BARD1 Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of BARD1 Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BARD1 Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

BARD1 Life Sciences Aktienanalyse

What does BARD1 Life Sciences do?

BARD1 Life Sciences Ltd. is an Australian biotechnology company specializing in the development of diagnostics and therapeutics for cancer. The company was founded in 1999 and is headquartered in Sydney. BARD1 Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating BARD1 Life Sciences's Shares Outstanding

BARD1 Life Sciences's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in BARD1 Life Sciences’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding BARD1 Life Sciences’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in BARD1 Life Sciences’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about BARD1 Life Sciences stock

How many stocks are there of BARD1 Life Sciences?

The current number of stocks of BARD1 Life Sciences is 77.27 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of BARD1 Life Sciences are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of BARD1 Life Sciences evolved in recent years?

The number of shares of BARD1 Life Sciences has increased by 70.01% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. BARD1 Life Sciences as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of BARD1 Life Sciences?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does BARD1 Life Sciences pay?

Over the past 12 months, BARD1 Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BARD1 Life Sciences is expected to pay a dividend of 0 AUD.

What is the dividend yield of BARD1 Life Sciences?

The current dividend yield of BARD1 Life Sciences is .

When does BARD1 Life Sciences pay dividends?

BARD1 Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BARD1 Life Sciences?

BARD1 Life Sciences paid dividends every year for the past 0 years.

What is the dividend of BARD1 Life Sciences?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BARD1 Life Sciences located?

BARD1 Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von BARD1 Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BARD1 Life Sciences from 9/16/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did BARD1 Life Sciences pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of BARD1 Life Sciences in the year 2023?

In the year 2023, BARD1 Life Sciences distributed 0 AUD as dividends.

In which currency does BARD1 Life Sciences pay out the dividend?

The dividends of BARD1 Life Sciences are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BARD1 Life Sciences

Our stock analysis for BARD1 Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BARD1 Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.